ImmunityBio, Inc. (IBRX)
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?
IBRX stock surges nearly 300% YTD as Anktiva sales jump and global approvals expand, while premium valuation and single-drug reliance raise questions.
Why Is ImmunityBio Stock Soaring On Friday?
ImmunityBio Inc. (NASDAQ: IBRX) shares are up on Friday morning as the company completed its manufacturing engineering programs for its NK cell therapy platform.
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines aiming to address a specific type of cancer with particular dedicated mechanisms.
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up
IBRX wins conditional EU approval for its Anktiva+BCG bladder cancer combo, sending shares soaring 41.9% and expanding its global footprint to 33 countries.
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ImmunityBio: The Story Surrounding Anktiva So Far
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early efficacy and manageable safety. IBRX's Anktiva is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer, with robust commercial traction—FY25 revenue reached ~$113 million, up 700% YoY. Key pipeline catalysts include upcoming trial readouts in bladder cancer and glioblastoma; positive data could drive further upside, but valuation is highly sensitive to setbacks.
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.
ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results
IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma without chemo or lymphodepletion.
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphoma
Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in patients treated with its off-the-shelf CD19 CAR-NK cell therapy in Waldenström non-Hodgkin's lymphoma, adding to recent momentum driven by strong sales growth for its approved immunotherapy Anktiva. ImmunityBio said on Friday that follow-up from its ongoing Phase 1/2 QUILT-106 study demonstrated sustained complete responses lasting up to 15 months in evaluable patients, with 100% disease control observed to date.
ImmunityBio: Why I Am Upgrading To A Buy For 2026
ImmunityBio is upgraded to Buy for 2026, reflecting improving Anktiva data and potential label expansions in NMIBC and NSCLC. IBRX reported 2025 product revenue of $113m, up 700% year-on-year, but losses remain heavy and commercial traction is not yet spectacular. Anktiva shows superior duration of response versus competitors and promising survival data in NSCLC, supporting long-term revenue potential.
